Interní Med. 2012; 14(8-9): 312-317

Hyponatremia: diagnostic process and new therapeutic approaches

MUDr.Jan Jiskra, Ph.D.
3. interní klinika 1. LF UK a VFN, Praha

Hyponatremia (decreased serum Na+ bellow low limit of a laboratory method – usually 135–137 mmol/l) is frequent abnormality. Even

asymptomatic, hyponatremia is linked with increased morbidity and mortality. Correct diagnosis is based on evaluation of serum osmolality

and tonicity, volume of extracellular fluid and concentration of Na+ in urine. Acute severe hyponatremia (<120 mmol/l) must

be treated with hypertonic saline immediately. Chronic hyponatremia should be treated with respect on its type (hypo-, eu- and hypervolemic

hyponatremia) and cause. Rapid correction of chronic hyponatremia can lead to osmotic brain demyelination. If hypervolemic

hyponatremia (chronic heart failure, liver cirrhosis and nephrotic syndrome) is excluded, one half of cases of hyponatremia are caused by

SIADH (syndrome of inappropriate antidiuretic hormone secretion). Therapy of SIADH is based on fluid restriction. If this is not effective

or is not tolerated by patient, vaptans (vasopressin V2 receptor antagonists in kidneys) can be used.

Keywords: hyponatremia, serum osmolality, extracellular fluid volume, syndrome of inappropriate antidiuretic hormone secretion

Published: September 20, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jiskra J. Hyponatremia: diagnostic process and new therapeutic approaches. Interní Med. 2012;14(8-9):312-317.
Download citation

References

  1. Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol, 2010; 21: 705-712. Go to original source... Go to PubMed...
  2. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med, 2007; 356: 2064-2072. Go to original source... Go to PubMed...
  3. Esposito P, Piotti G, Bianzina S, et al. The syndrome of inappropriate antidiuresis: pathophysiology, clinical management and new therapeutic options. Nephron Clin Pract, 2011; 119: 62-73. Go to original source... Go to PubMed...
  4. Finley JJ 4th, Konstam MA, Udelson JE. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation, 2008; 118: 410-421. Go to original source... Go to PubMed...
  5. Gill G, Huda B, Boyd A, et al. Characteristics and mortality of severe hyponatraemia - a hospital-based study. Clinical Endocrinology 2006; 65: 246-249. Go to original source... Go to PubMed...
  6. Greenberg A, Lehrich RW. Treatment of chronic hyponatremia: now we know how, but do we know when or if? J Am Soc Nephrol, 2010; 21: 552-555. Go to original source... Go to PubMed...
  7. Hannon MJ, Thompson CJ. The syndrome of inappropriate antidiuretic hormone: prevalence, causes and consequences. Eur J Endocrinol, 2010; 162(Suppl 1): S5-12. Smith DM, McKenna K, Thompson CJ. Hyponatraemia. Clin Endocrinol (Oxf), 2000; 52: 667-678. Go to original source... Go to PubMed...
  8. Hoorn EJ, van der Lubbe N, Zietse R. SIADH and hyponatraemia: why does it matter? NDT Plus, 2009; 2(Suppl 3): iii5-iii11. Go to original source... Go to PubMed...
  9. Janicic N, Verbalis JG. Evaluation and management of hypoosmolality in hospitalized patients. Endocrinol Metab Clin North Am, 2003; 32: 459-481. Go to original source... Go to PubMed...
  10. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. J Am Med Assoc, 2007; 297: 1319-1331. Go to original source... Go to PubMed...
  11. Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med, 2006; 119: 71.e1-8. Go to original source... Go to PubMed...
  12. Sajadieh A, Binici Z, Mouridsen MR, et al. Mild hyponatremia carries a poor prognosis in community subjects. American Journal of Medicine, 2009; 122: 679-686. Go to original source... Go to PubMed...
  13. Sherlock M, O'Sullivan E, Agha A, et al. The incidence and pathophysiology of hyponatraemia after subarachnoid haemorrhage. Clinical Endocrinology, 2006; 64: 250-254. Go to original source... Go to PubMed...
  14. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2 receptor antagonist, for hyponatremia. N Engl J Med, 2006; 355: 2099-2112. Go to original source... Go to PubMed...
  15. Schwartz WB, Bennett W, Curelop S, et al. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med, 1957; 23: 529-542. Go to original source... Go to PubMed...
  16. Smith DM, McKenna K, Thompson CJ. Hyponatraemia. Clin Endocrinol (Oxf), 2000; 52: 667-678. Go to original source... Go to PubMed...
  17. Vaidya C, Ho W, Freda BJ. Management of hyponatremia: providing treatment and avoiding harm. Cleve Clin J Med, 2010; 77: 715-726. Go to original source... Go to PubMed...
  18. Verbalis JG, Barsony J, Sugimura Y, et al. Hyponatremia induced osteoporosis. J Bone Miner Res, 2010; 25: 554-563. Go to original source... Go to PubMed...
  19. Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med, 2007; 120(Suppl 1): S1-21. Go to original source... Go to PubMed...
  20. Zilberberg MD, Exuzides A, Spalding J, et al. Hyponatremia and hospital outcomes among patients with pneumonia: a retrospective cohort study. BMC Pulmonary Medicine, 2008; 8: 16. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.